Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus

Journal of Theoretical Biology

Volumn 245, Issue 1, 2007, Pages 1-8

  Zurakowski, Ryan ^a   Wodarz, Dominik ^b  

^a UNIVERSITY OF DELAWARE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mathematical modeling; Oncolytic viruses; ONYX 015; Optimal control

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONCOLYTIC ADENOVIRUS; ONYX 015; PROTEIN P53;

CANCER; DISEASE TREATMENT; MUTATION; NUMERICAL MODEL; RECOMBINATION; TUMOR; VIRUS;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; DRUG INHIBITION; IN VITRO STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; TARGET CELL; VIRUS MUTATION; VIRUS PARTICLE; VIRUS REPLICATION; VULNERABLE POPULATION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CELL CYCLE; COMBINED MODALITY THERAPY; DRUG SYNERGISM; GENE THERAPY; HUMANS; MATHEMATICS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, VIRUS; RECOMBINATION, GENETIC; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 33846815153     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2006.09.029     Document Type: Article

References (16)

1. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., and Finberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 5304 (1997) 1320-1323
2. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., and McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 5286 (1996) 373-376
3. Fortner J.G., Klimstra D.S., Senie R.T., and Maclean B.J. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann. Surg. 223 2 (1996) 147-153
4. Gallagher W.M., and Brown R. p53-oriented cancer therapies: current progress. Ann. Oncol. 10 2 (1999) 139-150
5. Hecht J.R., Bedford R., Abbruzzese J.L., Lahoti S., Reid T.R., Soetikno R.M., Kirn D.H., and Freeman S.M. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9 2 (2003) 555-561
6. Hidaka C., Milano E., Leopold P.L., Bergelson J.M., Hackett N.R., Finberg R.W., Wickham T.J., Kovesdi I., Roelvink P., and Crystal R.G. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103 4 (1999) 579-587
7. Kanerva A., and Hemminki A. Adenoviruses for treatment of cancer. Ann. Med. 37 1 (2005) 33-43
8. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., Randlev B., Gillenwater A.M., Bruso P., Kaye S.B., Hong W.K., and Kirn D.H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6 8 (2000) 879-885
9. Mathias P., Wickham T., Moore M., and Nemerow G. Multiple adenovirus serotypes use alpha v integrins for infection. J. Virol. 68 10 (1994) 6811-6814
10. Mulvihill S., Warren R., Venook A., Adler A., Randlev B., Heise C., and Kirn D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 8 4 (2001) 308-315
11. Rauen K.A., Sudilovsky D., Le J.L., Chew K.L., Hann B., Weinberg V., Schmitt L.D., and McCormick F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 62 13 (2002) 3812-3818
12. Reid T., Galanis E., Abbruzzese J., Sze D., Andrews J., Romel L., Hatfield M., Rubin J., and Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8 21 (2001) 1618-1626
13. Ries S., and Korn W.M. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer 86 1 (2002) 5-11
14. Ries S.J., Brandts C.H., Chung A.S., Biederer C.H., Hann B.C., Lipner E.M., McCormick F., and Korn W.M. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6 10 (2000) 1128-1133
15. Wickham T.J., Filardo E.J., Cheresh D.A., and Nemerow G.R. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell. Biol. 127 1 (1994) 257-264
16. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res. 61 8 (2001) 3501-3507